Heart failure & cardiomyopathies
Implications of SGLT2 Inhibitors, GLP-1RAs, and Nonsteroidal MRAs on the Anticipated Burden of Heart Failure
Authors' conclusion
The projected burden of HF in the U.S. is substantial. A risk-based approach to preventive treatment may help reduce this considerably. The feasibility of such an approach deserves further investigation.
Study context
- Population
- Persons in the United States 30–79 years of age without cardiovascular disease at baseline
- Comparison
- Projected impact of sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists on the estimated burden of HF
- Outcome
- U.S. adults 30-79 years of age without established cardiovascular disease who will develop HF
- Follow-up
- Over 10 years
Methodological detailsnationally representative sample
- Nationally representative sample
Main finding
As reported in the abstract
Sodium-glucose cotransporter 2 inhibitor
5.1 million
95% CI 4.7-5.4 million
Glucagon-like peptide-1 receptor agonists
5.2 million
95% CI 4.8-5.6 million
Nonsteroidal mineralocorticoid receptor antagonists
5.4 million
95% CI 5.0-5.7 million
Combination therapy
4.8 million
95% CI 4.4-5.2 million
- Estimated U.S. adults who will develop HF, before the treatment estimates
- 5.5 million (95% CI: 5.1-5.8 million)
Further findings
Combination therapy in eligible persons with an estimated 10-year HF risk of ≥10%
- Eligible participants
- 6.8 million (95% CI: 6.1-7.5 million)
- Fewer cases of HF
- 498,000 (95% CI: −663,000 to −319,000)
- Number needed to treat to prevent 1 incident case
- 14 (95% CI: 10-22)
Original publication
Implications of SGLT2 Inhibitors, GLP-1RAs, and Nonsteroidal MRAs on the Anticipated Burden of Heart Failure. JACC Heart Fail. Published 2 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →